Business Context and Reporting Period
Company: Oncolytics Biotech Inc. (ONCY)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered oncolytic reovirus immunotherapy. The drug selectively replicates in RAS-mutated tumors to activate the immune system. The company has no approved products and generates no operating revenue. Its primary focus is advancing clinical programs for gastrointestinal cancers (colorectal, anal, and pancreatic) and breast cancer.
Key Financial Metrics
| Metric (in thousands USD) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(28,759) | $(22,794) |
| Operating Expenses | $28,725 | $25,542 |
| Cash and Cash Equivalents (Year End) | $5,202 | $11,079 |
| Accumulated Deficit | $(429,495) | $(400,736) |
| Net Cash Used in Operating Activities | $(20,112) | $(19,883) |
| Net Cash Provided by Financing Activities | $14,120 | $5,028 |
Liquidity: As of December 31, 2025, the company held $5.2 million in cash. Management states this is insufficient to fund planned operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern without additional financing.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $6.0 million (26%) year-over-year, driven primarily by a $5.3 million increase in General and Administrative (G&A) expenses.
- G&A Expenses: Rose from $10.1 million to $15.4 million. This increase was largely due to professional fees associated with the company's "Domestication" (reincorporation from Canada to Nevada), the Special Meeting of Shareholders, and voluntary delisting from the Toronto Stock Exchange.
- R&D Expenses: Decreased by $2.1 million (14%) to $13.3 million. This reduction was driven by lower clinical trial costs (completion of the BRACELET-1 study) and fewer cGMP production runs, partially offset by increased personnel costs related to executive transitions.
- Financing Activity: The company raised approximately $14.1 million in net proceeds during 2025 through At-The-Market (ATM) offerings and a Standby Equity Purchase Agreement (SEPA), compared to $5.0 million in 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The company does not provide specific financial guidance. Management expects to continue incurring substantial losses until pelareorep becomes commercially viable. The focus for 2026 is on advancing registration-enabling clinical studies in metastatic colorectal cancer (mCRC) and second-line or later squamous cell carcinoma of the anal canal (SCAC).
Material Risks and Contingencies
- Going Concern: The filing explicitly states substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months. Continued operations depend on raising additional capital.
- Domestication: The company is in the process of reincorporating from British Columbia, Canada, to Nevada, USA. This process is expected to be effective around March 31, 2026, and involves changes to shareholder rights and potential tax consequences.
- Regulatory & Clinical: Success depends on the efficacy of pelareorep in ongoing trials and obtaining FDA approval. The company relies on third-party manufacturers and partners (e.g., Roche for atezolizumab) for clinical supply.
- Stock Price: The company previously received a delinquency notice from Nasdaq regarding minimum bid price requirements but regained compliance during the cure period.
Unusual Items
The company recognized a non-cash fair value loss of $388,000 related to the termination of its SEPA Arrangement with Alumni Capital LP in August 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.2 million cash balance against the stated need for additional financing within 12 months.
- Domestication Status: Confirm the completion of the reincorporation to Nevada and any associated tax implications for shareholders.
- Clinical Milestones: Monitor upcoming data readouts for the mCRC and SCAC trials, which are critical for securing partnerships or regulatory approval.
- Capital Raising: Track the utilization of the remaining ~$39 million capacity under the ATM facility and any new equity issuances.
- Partnership Progress: Assess the status of discussions with potential strategic partners to fund the proposed Phase 3 pancreatic cancer study.